1
|
Berlotti M, Di Grande S, Cavalieri S. Proposal of a Machine Learning Approach for Traffic Flow Prediction. Sensors (Basel) 2024; 24:2348. [PMID: 38610556 PMCID: PMC11014399 DOI: 10.3390/s24072348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/04/2024] [Revised: 03/28/2024] [Accepted: 04/04/2024] [Indexed: 04/14/2024]
Abstract
Rapid global urbanization has led to a growing urban population, posing challenges in transportation management. Persistent issues such as traffic congestion, environmental pollution, and safety risks persist despite attempts to mitigate them, hindering urban progress. This paper focuses on the critical need for accurate traffic flow forecasting, considered one of the main effective solutions for containing traffic congestion in urban scenarios. The challenge of predicting traffic flow is addressed by proposing a two-level machine learning approach. The first level uses an unsupervised clustering model to extract patterns from sensor-generated data, while the second level employs supervised machine learning models. Although the proposed approach requires the availability of data from traffic sensors to realize the training of the machine learning models, it allows traffic flow prediction in urban areas without sensors. In order to verify the prediction capability of the proposed approach, a real urban scenario is considered.
Collapse
Affiliation(s)
- Mariaelena Berlotti
- Department of Electrical Electronic and Computer Engineering, University of Catania, Viale A. Doria 6, 95125 Catania, Italy; (S.D.G.); (S.C.)
| | | | | |
Collapse
|
2
|
Cavalieri S, Gambadoro S. Digital Twin of a Water Supply System Using the Asset Administration Shell. Sensors (Basel) 2024; 24:1360. [PMID: 38474896 DOI: 10.3390/s24051360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/22/2024] [Revised: 02/17/2024] [Accepted: 02/18/2024] [Indexed: 03/14/2024]
Abstract
The concept of digital twins is one of the fundamental pillars of Industry 4.0. Digital twin allows the realization of a virtual model of a real system, enhancing the relevant performance (e.g., in terms of production rate, risk prevention, energy saving, and maintenance operation). Current literature presents many contributions pointing out the advantages that may be achieved by the definition of a digital twin of a water supply system. The Reference Architecture Model for Industry 4.0 introduces the concept of the Asset Administration Shell for the digital representation of components within the Industry 4.0 ecosystem. Several proposals are currently available in the literature considering the Asset Administration Shell for the realization of a digital twin of real systems. To the best of the authors' knowledge, at the moment, the adoption of Asset Administration Shell for the digital representation of a water supply system is not present in the current literature. For this reason, the aim of this paper is to present a methodological approach for developing a digital twin of a water supply system using the Asset Administration Shell metamodel. The paper will describe the approach proposed by the author and the relevant model based on Asset Administration Shell, pointing out that its implementation is freely available on the GitHub platform.
Collapse
Affiliation(s)
- Salvatore Cavalieri
- Department of Electrical Electronic and Computer Engineering, University of Catania, Viale A. Doria 6, 95125 Catania, Italy
| | - Salvatore Gambadoro
- Department of Electrical Electronic and Computer Engineering, University of Catania, Viale A. Doria 6, 95125 Catania, Italy
| |
Collapse
|
3
|
Cavalieri S, Gambadoro S. Proposal of Mapping Digital Twins Definition Language to Open Platform Communications Unified Architecture. Sensors (Basel) 2023; 23:2349. [PMID: 36850947 PMCID: PMC9965445 DOI: 10.3390/s23042349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 01/12/2023] [Revised: 02/15/2023] [Accepted: 02/18/2023] [Indexed: 06/18/2023]
Abstract
The concept of Digital Twin is of fundamental importance to meet the main requirements of Industry 4.0. Among the standards currently available to realize Digital Twins there is the Digital Twins Definition Language. Digital Twin requires exchange of data with the real system it models and with other applications that use the digital replica of the system. In the context of Industry 4.0, a reference standard for an interoperable exchange of information between applications, is Open Platform Communications Unified Architecture. The authors believe that interoperability between Digital Twins and Open Platform Communications Unified Architectures communication standard should be enabled. For this reason, the main goal of this paper is to allow a Digital Twin based on the Digital Twins Definition Language to exchange data with any applications compliant to the Open Platform Communications Unified Architecture. A proposal about the mapping from Digital Twins Definition Language to the Open Platform Communications Unified Architecture will be presented. In order to verify the feasibility of the proposal, an implementation has been made by the authors, and its description will be introduced in the paper. Furthermore, the main results of the validation process accomplished on the basis of this implementation will be given.
Collapse
|
4
|
Trama A, Matsuda T, Charvat H, Chiang RJ, van Gestel A, Martin F, Geleijnse G, Bonfarnuzzo S, Licitra L, Cavalieri S, Resteghini C, Gatta G, Botta L. 224O Survival differences between EU and Asia for head and neck cancer: Results of the RARECAREnet-Asia collaboration. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
5
|
Ho E, De Cecco L, Cavalieri S, Serafini M, Pistore F, Lenoci D, Hoebers F, Brakenhoff R, Leemans C, Scheckenbach K, Poli T, Campbell S, Yang K, Eschrich S, Koyfman S, Licitra L, Torres-Roca J, Scott J. Genomic Adjusted Radiation Dose (GARD) Predicts Overall Survival and Outperforms AJCC 8th Edition in Prognostication of HPV-Positive Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
6
|
Licitra L, Serafini M, Pistore F, Canevari S, Resteghini C, Cavalieri S, Trama A, De Cecco L. 232MO Transcriptomic and tumor microenvironment landscape of EBV related nasopharyngeal carcinoma in endemic and non-endemic areas. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
|
7
|
Cavalieri S, Vener C, LeBlanc M, Lopez Perez L, Fico G, Resteghini C, Monzani D, Marton G, Moreira-Soares M, Filippidou D, Almeida A, Bilbao A, Mehanna H, Singer S, Thomas S, Lacerenza L, Manfuso A, Mercalli F, Martinelli E, Licitra L. 708TiP BD4QoL: A multicenter randomized trial for monitoring quality of life (QoL) by intelligent tools in head and neck cancer (HNC) survivors after curative treatment. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.832] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
8
|
Sabri A, Cavalieri S, Ahmad F, Martin S, Abushattal A. Bacillus cereus Bacteremia: An Unusual Case Following Food Poisoning. Am J Clin Pathol 2021. [DOI: 10.1093/ajcp/aqab191.282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction/Objective
Bacillus cereus is a spore-forming, gram-positive rod, well known for causing food poisoning. In addition, this bacterium often presents as a contaminant of blood cultures. Differentiating true bacteremia from contamination of blood samples is important as it has treatment implications. Early recognition is necessary, as it can cause septic shock if untreated. We present a challenging case of food poisoning with concomitant bacteremia in a young patient with a history of diabetes mellitus (DM), celiac disease, and new-onset chronic kidney disease (CKD).
Methods/Case Report
A 23-year-old adult male with a history of DM, new-onset CKD, and celiac disease presented with nausea, intermittent vomiting, and lower abdominal pain for 2 weeks. On initial evaluation, he had normal blood pressure but tachypnea and tachycardia. Physical examination was significant for left lower quadrant and flank tenderness. The symptoms were persistent and progressed to point that he could not tolerate meals due to vomiting. Two weeks earlier, he presented with similar complaints along with dysuria and was treated for suspected urinary tract infection with Co-trimoxazole. This time, further workup revealed normal white blood cell count (11.8 k/µL) with 81% neutrophils, elevated creatinine (3.56 mg/dL), blood urea nitrogen (49 mg/dL), and procalcitonin (0.39 ng/mL), with abnormal urinalysis showing increased turbidity, pyuria, and nitrituria. He was started on ceftriaxone, fluids, antiemetics and was admitted to the hospital for further management. The urine culture had no bacterial growth. Two sets of peripheral blood cultures (different sites at different times) had gram-positive rods which eventually turned out to be B. cereus, identified by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). Levofloxacin was started, and he reported improvement in nausea and vomiting by the next day of admission and was discharged.
Results (if a Case Study enter NA)
NA
Conclusion
Differentiating true B. cereus bacteremia from blood sample contamination is important. Additionally, no symptoms are specific for B. cereus-associated food poisoning, and the presence of risk factors doesn’t always favor this entity over other entities, hence adding difficulty to the diagnosis. A high index of suspicion is needed, as early intervention can prevent the development of life-threatening complications.
Collapse
Affiliation(s)
- A Sabri
- Department of Pathology, Creighton University - School of Medicine, Omaha, Nebraska, UNITED STATES
| | - S Cavalieri
- Department of Pathology, Creighton University - School of Medicine, Omaha, Nebraska, UNITED STATES
| | - F Ahmad
- Division of Infectious Diseases, Department of Internal Medicine, Creighton University - School of Medicine, Omaha, Nebraska, UNITED STATES
| | - S Martin
- Department of Internal Medicine, Creighton University - School of Medicine, Omaha, Nebraska, UNITED STATES
| | - A Abushattal
- University of Jordan - School of Medicine, Amman, JORDAN
| |
Collapse
|
9
|
Psyrri A, Mehanna H, Economopoulou P, Porceddu S, Waldron J, Wen Ong E, Chua M, Saba N, Basté N, Cavalieri S, Fountzilas G, Licitra L. 929TiP HERODOTUS: Head and neck cancers international COVID-19 collaboration: An international registry on head and neck cancer with COVID-19. Ann Oncol 2021. [PMCID: PMC8454395 DOI: 10.1016/j.annonc.2021.08.1339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
10
|
Alfieri S, Marceglia S, Filippini D, Bergamini C, Resteghini C, Cavalieri S, Peris K, Sollena P, Piccerillo A, Gualdi G, Ascierto P, Curvietto M, Palla M, De Giorgi V, Eibenschutz L, Spagnolo F, Orlandi E, Locati L, Licitra L, Bossi P. 1065P A retrospective multicenter Italian analysis of the effect of longer vismodegib intake in 68 basal cell carcinoma patients who achieved clinical complete remission. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1450] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
11
|
Platini F, Cavalieri S, Alfieri S, Bergamini C, Resteghini C, Bottiglieri A, Colombo E, Mazzeo L, Licitra L, Paolini B, Seregni E, Locati LD. Late toxicities burden in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. Endocrine 2021; 73:641-647. [PMID: 33797698 DOI: 10.1007/s12020-021-02702-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2021] [Accepted: 03/17/2021] [Indexed: 02/02/2023]
Abstract
PURPOSE Radioactive-iodine (RAI)-resistant differentiated thyroid cancer (DTC) patients benefit from multi-kinase inhibitors (MKIs), such as lenvatinib. Incidence of treatment-related (TR) late toxicities has been not yet described. METHODS From January 2015 to June 2019 we retrospectively reviewed clinical records of patients with RAI-resistant DTC treated with lenvatinib at Istituto Nazionale dei Tumori (Milan, Italy). New side effect of any grade, appeared after 12 months of lenvatinib, was defined as late adverse event (AE). Descriptive analyses were performed. Survival curves were estimated with Kaplan-Meier method and compared with log-rank test. RESULTS Thirty-seven patients were included, 65% had ≥65 years and 68% were female. Thirty patients received lenvatinib for >12 months. Lenvatinib was started at ≤20 mg/daily in 59% of patients, 64% were ≥65 years. The frequency of late AEs was 80% and cardiovascular toxicity was the most common (57%). There was no difference in the incidence of late AEs between younger/older population (77% and 82%, respectively). Median lenvatinib treatment duration (TD) was 39.96 months (95% CI 21.64-NR): 39.96 months for patients <65 years (95% CI: 13.25-NR) and 37.53 months for those ≥65 years, respectively (95% CI: 15.85-NR). Median overall survival (OS) was 39.96 months (95% CI: 21.84-NR), no statistically differences in OS was observed between younger (<65 years) and older patients (≥65 years) (HR 1.013; 95% CI 0.963-1.065; p = 0.62). CONCLUSION Late toxicity burden of lenvatinib is not negligible. Cardiovascular toxicity remains the principal side effect even after a prolonged lenvatinib exposition.
Collapse
Affiliation(s)
- F Platini
- Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - S Cavalieri
- Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - S Alfieri
- Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - C Bergamini
- Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - C Resteghini
- Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - A Bottiglieri
- Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - E Colombo
- Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - L Mazzeo
- Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - L Licitra
- Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- Medical Oncology Department, University of Milan, Milan, Italy
| | - B Paolini
- Pathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - E Seregni
- Struttura di Terapia Medico Nucleare ed Endocrinologia U.O. Medicina Nucleare, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - L D Locati
- Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
| |
Collapse
|
12
|
Keek S, Wesseling F, Woodruff H, van Timmeren J, Nauta I, Hoffmann T, Cavalieri S, Calareso G, Primakov S, Leijenaar R, Licitra L, Ravanelli M, Scheckenbach K, Poli T, Lanfranco D, Vergeer M, Leemans R, Brakenhoff R, Hoebers F, Lambin P. OC-0642 A radiomics based prognostic model for patients with head and neck squamous cell carcinoma. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)06998-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
13
|
Cavalieri S. Semantic Interoperability between IEC 61850 and oneM2M for IoT-Enabled Smart Grids. Sensors (Basel) 2021; 21:s21072571. [PMID: 33917602 PMCID: PMC8038825 DOI: 10.3390/s21072571] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/10/2021] [Revised: 03/27/2021] [Accepted: 04/02/2021] [Indexed: 11/26/2022]
Abstract
In the era of Industry 4.0, pervasive adoption of communication technologies based on the Internet of Things represents a very strong requirement in several domains. In the smart grid domain, there is the need to overcome one of the main limitations of the current electric grid, allowing the use of heterogeneous devices capable of measuring, monitoring and exchanging information about grid components. For this reason, current literature often presents research activities about enabling internet of things (IoT) in smart grids; in particular, several proposals aim to realize interworking between IoT and smart grid communication standards, allowing exchange of information between IoT devices and the electrical grid components. Semantic interoperability should be achieved in an interworking solution in order to provide a common meaning of the data exchanged by heterogeneous devices, even if they belong to different domains. Until now, semantic interoperability remains an open challenge in the smart grid field. The paper aims to propose a novel solution of interworking between two of the most used communication systems in smart grids and IoT domains, i.e., IEC 61850 and oneM2M, respectively. A semantic interoperability solution is also proposed to be used in the interworking scheme here presented.
Collapse
Affiliation(s)
- Salvatore Cavalieri
- Department of Electrical Electronic and Computer Engineering, University of Catania, Viale A. Doria 6, 95125 Catania, Italy
| |
Collapse
|
14
|
Cavallo A, Rancati T, Iacovelli N, Facchinetti N, Alfieri S, Cavalieri S, Giandini T, Cicchetti A, Ingargiola R, Romanello D, Di Biaso S, Sabetti M, Fallai C, Licitra L, Locati L, Pignoli E, Valdagni R, Orlandi E. PD-0545: Validation of a predictive model for salivary dysfunction during chemo-IMRT for head-neck cancer. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00567-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
15
|
Orlandi E, Calareso G, Tenconi C, Rancati T, Iacovelli N, Cavallo A, Facchinetti N, Ingargiola R, Ivaldi E, Romanello D, Corino V, Valdagni R, Cavalieri S, Alfieri S, Licitra L, Pignoli E, Mainardi L, Fallai C, Bologna M. PO-1577: Baseline MRI-radiomics can predict overall survival in non endemic nasopharyngeal cancer patients. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01595-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
16
|
Vicente Blanco V, Lopez Perez L, Hernandez L, Galeote Checa G, Licitra L, Cavalieri S, Fico G, Arredondo M. 1934P Research and contextual inquiry on information and communication technologies point of care systems for cancer follow-up. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
17
|
Magnavita N, Angelillo A, Anniballi A, Cavalieri S, Di Prinzio RR, Pompei A, Ragozzino R, Rallo G, Voza C. Workplace violence, early neurological symptoms, and metabolic or psychiatric disorders. Eur J Public Health 2020. [DOI: 10.1093/eurpub/ckaa165.660] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Workplace violence is ubiquitous. Neuropsychological symptoms, such as headaches and sleep problems, may be the earliest consequences of violent acts, and in turn are associated with an increased risk of cardiovascular and psychiatric disorders. Systematic research on this topic can help treatment and prevention.
905 health & social workers (male 331, 36.6%; mean age 46 + 11.4 years), during their periodical medical examination in the workplace, were asked to fill in a standardized questionnaire containing the Violent Incident Form on the episodes of violence suffered, the Headache Impact Test on headache and the PSQI on sleep problems. Anxiety and depression were evaluated with the Goldberg scale.
Workers reported having suffered physical assaults (5.2%), threats (11.5%), and harassment (10.2%) in the previous year. Workers who experienced violence had an increased risk of headaches (OR 2.80, CI95% 1.55-5.05 for physical violence, OR 1.83 CI95% 1.21-2.78 for threats, OR 2.46 CI95% 1.59-3.96 for harassment) and of sleep problems (OR 2.46, CI95% 1.33-4.57 for physical violence, OR 2.81 CI95% 1.82-4.33 for threats, OR 5.09 CI95% 3.04-8.51 for harassment).
Headache and sleep problems were significantly correlated with the components of the metabolic syndrome (hypertension, dyslipidemia, hyperglycaemia, obesity): Pearson's r was 0.069 for headache (p < 0.05), 0.142 for sleep quality (p < 0.001). Head and sleep problems were also correlated with anxiety (r = 0.519 and 0.670, respectively) and with depression (r = 0.457 and 0.619).
Violence at work was associated with an increased risk of headaches and sleep problems. These symptoms were associated with the components of the metabolic syndrome, with anxiety and with depression.
Early detection of symptoms such as headaches and sleep problems allows individual treatment measures to be put in place. The identification of the causes of these morbid phenomena allows to implement primary prevention measures in the workplace.
Key messages
Workplace violence causes headache and sleep problems, which, in turn, are associated with metabolic and psychiatric disorders. Periodic surveillance of workers is useful for improving public health.
Collapse
Affiliation(s)
- N Magnavita
- School of Occupational Health, Università Cattolica del Sacro Cuore, Rome, Italy
- Department of Woman and Child Health and Public Health - Pub, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - A Angelillo
- School of Occupational Health, Università Cattolica del Sacro Cuore, Rome, Italy
| | - A Anniballi
- School of Occupational Health, Università Cattolica del Sacro Cuore, Rome, Italy
| | - S Cavalieri
- School of Occupational Health, Università Cattolica del Sacro Cuore, Rome, Italy
| | - R R Di Prinzio
- School of Occupational Health, Università Cattolica del Sacro Cuore, Rome, Italy
| | - A Pompei
- School of Occupational Health, Università Cattolica del Sacro Cuore, Rome, Italy
| | - R Ragozzino
- School of Occupational Health, Università Cattolica del Sacro Cuore, Rome, Italy
| | - G Rallo
- School of Occupational Health, Università Cattolica del Sacro Cuore, Rome, Italy
| | - C Voza
- School of Occupational Health, Università Cattolica del Sacro Cuore, Rome, Italy
| |
Collapse
|
18
|
Pumpo MD, Barbara A, La Milia DI, Tamburrano A, Vallone D, Gentili A, Cavalieri S, Viora C, Berloco F, Laurenti P. Flu vaccination coverage in a large Italian teaching hospital: the example of the leaders. Eur J Public Health 2019. [DOI: 10.1093/eurpub/ckz185.630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Annual flu vaccination among healthcare workers (HCWs) is recommended to prevent influenza and to avoid its transmission especially to frail patients. In our teaching hospital, flu vaccination rate among HCWs has been growing during last 3 years. The aim of this study was therefore to describe the flu vaccination coverage across the past 3 years and to analyze which factors lead to such increase. We performed a cross-sectional study on all HCWs of Fondazione Policlinico Universitario “A. Gemelli” (FPG) hospital of Rome (Italy) to determine the flu vaccination coverage. Socio-demographic and occupational data were collected from hospital personnel records and included age, gender, previous flu vaccination, profession and workplace unit. On site vaccination plus academic detailing involving leaders have been the main strategies adopted in this last 3 years that have already proved to be effective in increasing vaccination coverage among HCWs. During the 2018-2019 season, we analyzed how the flu vaccination coverage among leaders (nurse coordinators and head physicians) could affect all HCWs coverage rate. Flu vaccination rate increased from 9.57% in the 2016-17 to 14.24% in the 2017-18 and to 22.38% in 2018-2019. A total of 4035 HCWs employed in the FPG were included in 2018-19. Concerning the role played by vaccination of leaders in increasing general vaccination coverage during the 2018-2019, the group of HCWs with a vaccinated leader showed a higher coverage rate (28.65%) than the group with a non-vaccinated leader (16.22%) (p < 0.0001). The results are preliminary. Flu vaccination coverage of HCWs in our hospital during the last 3 years has been increasingly higher. Vaccination of the leaders, in addition to previously implemented effective strategies, resulted to be a key factor in increasing flu vaccination coverage among all HCWs. Socio-demographic and occupational variables can significantly influence the coverage rate as well.
Key messages
Annual flu vaccination among healthcare workers (HCWs) is recommended to prevent influenza and to avoid its transmission especially to frail patients. This study shows the growing flu vaccination coverage rate in our teaching hospital and the effectiveness of the example given by the vaccinated leaders in increasing the coverage among all HCWs.
Collapse
Affiliation(s)
- M Di Pumpo
- Sezione di Igiene – Istituto di Sanità Pubblica, Università Cattolica del Sacro Cuore, Rome, Italy
| | - A Barbara
- Sezione di Igiene – Istituto di Sanità Pubblica, Università Cattolica del Sacro Cuore, Rome, Italy
| | - D I La Milia
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
| | - A Tamburrano
- Sezione di Igiene – Istituto di Sanità Pubblica, Università Cattolica del Sacro Cuore, Rome, Italy
| | - D Vallone
- Sezione di Igiene – Istituto di Sanità Pubblica, Università Cattolica del Sacro Cuore, Rome, Italy
| | - A Gentili
- Sezione di Igiene – Istituto di Sanità Pubblica, Università Cattolica del Sacro Cuore, Rome, Italy
| | - S Cavalieri
- Sezione di Igiene – Istituto di Sanità Pubblica, Università Cattolica del Sacro Cuore, Rome, Italy
| | - C Viora
- Sezione di Igiene – Istituto di Sanità Pubblica, Università Cattolica del Sacro Cuore, Rome, Italy
| | - F Berloco
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
| | - P Laurenti
- Sezione di Igiene – Istituto di Sanità Pubblica, Università Cattolica del Sacro Cuore, Rome, Italy
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
| |
Collapse
|
19
|
Zeneli A, Prati S, Nanni C, Zavoiu V, Filograna A, Cavalieri S, Ragonesi M, Quadrelli P, Bragagni M, Montalti S. Evaluating the role of clinical nurse specialist. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz277.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Locati L, Cavalieri S, Bergamini C, Resteghini C, Alfieri S, Calareso G, Bossi P, Quattrone P, Granata R, Galbiati D, Platini F, Orlandi E, Mariani L, Licitra L. PO-165 Phase 2 study on axitinib in recurrent/metastatic salivary gland cancer of upper aerodigestive tract. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)30331-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
21
|
van Boxtel W, Locati LD, van Engen-van Grunsven ACH, Bergamini C, Jonker MA, Fiets E, Cavalieri S, Tooten S, Bos E, Quattrone P, Verhaegh GW, Schalken JA, Licitra L, van Herpen CML. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma. Eur J Cancer 2019; 110:62-70. [PMID: 30771738 DOI: 10.1016/j.ejca.2018.12.035] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2018] [Revised: 12/18/2018] [Accepted: 12/22/2018] [Indexed: 10/27/2022]
Abstract
AIM Salivary duct carcinoma (SDC), an aggressive subtype of salivary gland cancer, is androgen receptor (AR)-positive in 67-96% of cases. In patients with locally recurrent and metastatic (R/M) AR-positive SDC, androgen deprivation therapy (ADT) has an overall response rate of 18-64.7%. In this study, we describe the efficacy of adjuvant ADT in patients with poor-risk (stage 4a) AR-positive SDC. METHODS This is a retrospective cohort study in which patients with stage 4a AR-positive SDC were offered adjuvant ADT, i.e. bicalutamide, luteinizing hormone-releasing hormone (LHRH) analogue or a combination of these after tumour resection. In the control group, data were collected on patients with stage 4a SDC who underwent a tumour resection but did not receive adjuvant ADT. RESULTS Twenty-two AR-positive SDC patients were treated with adjuvant ADT for a median duration of 12 months. The control group consisted of 111 SDC patients. After a median follow-up of 20 months in the ADT-treated patients and 26 months in the control group, the 3-year disease-free survival (DFS) was estimated as 48.2% (95% confidence interval [CI] 14.0-82.4%) and 27.7% (95% CI 18.5-36.9%) (P = 0.037). Multivariable Cox regression analysis showed a hazard ratio of 0.138 (95% CI 0.025-0.751, P = 0.022) for DFS and 0.064 (95% CI 0.005-0.764, P = 0.030) for overall survival (OS) in favour of the ADT-treated patients. CONCLUSION Poor-risk, AR-positive SDC patients who received adjuvant ADT have a significantly longer DFS compared with patients in the control group, who did not receive adjuvant ADT. For OS, this was just below and above the significance level, in case there was or was no correction for confounders.
Collapse
Affiliation(s)
- W van Boxtel
- Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 8, 6525 GA Nijmegen, the Netherlands
| | - L D Locati
- Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian 1, 20133 Milan, Italy
| | - A C H van Engen-van Grunsven
- Department of Pathology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, the Netherlands
| | - C Bergamini
- Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian 1, 20133 Milan, Italy
| | - M A Jonker
- Department for Health Evidence, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, the Netherlands
| | - E Fiets
- Department of Medical Oncology, Medical Center Leeuwarden, Henri Dunantweg 2, 8934 AD Leeuwarden, the Netherlands
| | - S Cavalieri
- Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian 1, 20133 Milan, Italy
| | - S Tooten
- Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 8, 6525 GA Nijmegen, the Netherlands
| | - E Bos
- Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 8, 6525 GA Nijmegen, the Netherlands
| | - P Quattrone
- Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian 1, 20133 Milan, Italy
| | - G W Verhaegh
- Department of Urology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, the Netherlands
| | - J A Schalken
- Department of Urology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, the Netherlands
| | - L Licitra
- Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian 1, 20133 Milan, Italy; University of Milan, Via Festa del Perdono, 7, 20122 Milan, Italy
| | - C M L van Herpen
- Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 8, 6525 GA Nijmegen, the Netherlands.
| | | |
Collapse
|
22
|
Cavalieri S, De Cecco L, Calareso G, Silva M, Gazzani S, Bologna M, Nauta I, Wesseling F, Lopez Perez L, Shefi R, Tountopoulos V, Fico G, Scheckenbach K, Brakenhoff R, Hoebers F, Canevari S, Poli T, Licitra L, Mainardi L. Genomics features (GF) and integration with MRI radiomics features (RF) to develop a prognostic model in oral cavity squamous cell carcinoma (OSCC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy287.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
23
|
Bossi P, Depenni R, cossu rocca M, Ferrari D, Azzarello G, Alù M, Nolè F, Codecà C, Boscolo G, Piccininni M, Cavalieri S, Pugliese G, Licitra L. Clinical prognostic factors in patients (pts) with recurrent and/or metastatic (RM) head and neck carcinoma (HNC) treated with cetuximab plus chemotherapy. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy287.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
24
|
Mancini C, Giorgio E, Rubegni A, Pradotto L, Bagnoli S, Rubino E, Prontera P, Cavalieri S, Di Gregorio E, Ferrero M, Pozzi E, Riberi E, Ferrero P, Nigro P, Mauro A, Zibetti M, Tessa A, Barghigiani M, Antenora A, Sirchia F, Piacentini S, Silvestri G, De Michele G, Filla A, Orsi L, Santorelli FM, Brusco A. Prevalence and phenotype of the c.1529C>T SPG7 variant in adult-onset cerebellar ataxia in Italy. Eur J Neurol 2018; 26:80-86. [PMID: 30098094 DOI: 10.1111/ene.13768] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2018] [Accepted: 08/07/2018] [Indexed: 12/17/2022]
Abstract
BACKGROUND AND PURPOSE Hereditary ataxias are heterogeneous groups of neurodegenerative disorders, characterized by cerebellar syndromes associated with dysarthria, oculomotor and corticospinal signs, neuropathy and cognitive impairment. Recent reports have suggested mutations in the SPG7 gene, causing the most common form of autosomal recessive spastic paraplegia (MIM#607259), as a main cause of ataxias. The majority of described patients were homozygotes or compound heterozygotes for the c.1529C>T (p.Ala510Val) change. We screened a cohort of 895 Italian patients with ataxia for p.Ala510Val in order to define the prevalence and genotype-phenotype correlation of this variant. METHODS We set up a rapid assay for c.1529C>T using restriction enzyme analysis after polymerase chain reaction amplification. We confirmed the diagnosis with Sanger sequencing. RESULTS We identified eight homozygotes and 13 compound heterozygotes, including two novel variants affecting splicing. Mutated patients showed a pure cerebellar ataxia at onset, evolving in mild spastic ataxia (alternatively) associated with dysarthria (~80% of patients), urinary urgency (~30%) and pyramidal signs (~70%). Comparing homozygotes and compound heterozygotes, we noted a difference in age at onset and Scale for the Assessment and Rating of Ataxia score between the two groups, supporting an earlier and more severe phenotype in compound heterozygotes versus homozygotes. CONCLUSIONS The SPG7 c.1529C>T (p.Ala510Val) mutants accounted for 2.3% of cerebellar ataxia cases in Italy, suggesting that this variant should be considered as a priority test in the presence of late-onset pure ataxia. Moreover, the heterozygous/homozygous genotype appeared to predict the onset of clinical manifestation and disease progression.
Collapse
Affiliation(s)
- C Mancini
- Department of Medical Sciences, University of Torino, Turin, Italy
| | - E Giorgio
- Department of Medical Sciences, University of Torino, Turin, Italy
| | - A Rubegni
- Molecular Medicine, IRCCS Fondazione Stella Maris, Pisa, Italy
| | - L Pradotto
- Division of Neurology and Neurorehabilitation, San Giuseppe Hospital, IRCCS Istituto Auxologico Italiano, Piancavallo, Italy
| | - S Bagnoli
- Department of Neuroscience, Psychology, Drug Research and Child's Health, University of Florence, Florence, Italy
| | - E Rubino
- Department of Neuroscience and Mental Health, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - P Prontera
- Medical Genetics Unit, Hospital S. Maria della Misericordia, Perugia, Italy
| | - S Cavalieri
- Department of Medical Sciences, University of Torino, Turin, Italy
| | - E Di Gregorio
- Department of Medical Sciences, University of Torino, Turin, Italy
| | - M Ferrero
- Department of Medical Sciences, University of Torino, Turin, Italy
| | - E Pozzi
- Department of Medical Sciences, University of Torino, Turin, Italy
| | - E Riberi
- Department of Medical Sciences, University of Torino, Turin, Italy
| | - P Ferrero
- Department of Neuroscience and Mental Health, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - P Nigro
- Clinica Neurologica, Azienda Ospedaliera - Università di Perugia, Perugia, Italy
| | - A Mauro
- Department of Neurosciences, University of Torino, Turin, Italy
| | - M Zibetti
- Department of Neuroscience and Mental Health, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - A Tessa
- Molecular Medicine, IRCCS Fondazione Stella Maris, Pisa, Italy
| | - M Barghigiani
- Molecular Medicine, IRCCS Fondazione Stella Maris, Pisa, Italy
| | - A Antenora
- Department of Neurosciences, Federico II University, Naples, Italy
| | - F Sirchia
- Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste, Italy
| | - S Piacentini
- Department of Neuroscience, Psychology, Drug Research and Child's Health, University of Florence, Florence, Italy
| | - G Silvestri
- Fondazione Policlinico Universitario IRCCS, A. Gemelli, Rome, Italy.,Università Cattolica del Sacro Cuore, Rome, Italy
| | - G De Michele
- Department of Neurosciences, Federico II University, Naples, Italy
| | - A Filla
- Department of Neurosciences, Federico II University, Naples, Italy
| | - L Orsi
- Department of Neuroscience and Mental Health, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - F M Santorelli
- Molecular Medicine, IRCCS Fondazione Stella Maris, Pisa, Italy
| | - A Brusco
- Department of Medical Sciences, University of Torino, Turin, Italy.,Medical Genetics Unit, Città della Salute e della Scienza Hospital, Turin, Italy
| |
Collapse
|
25
|
Cavalieri S, Perrone F, Miceli R, Ascierto PA, Locati LD, Bergamini C, Granata R, Alfieri S, Resteghini C, Galbiati D, Busico A, Paielli N, Patuzzo R, Maurichi A, Gallino G, Ruggeri R, Mariani L, Palla M, Licitra L, Bossi P. Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. Eur J Cancer 2018; 97:7-15. [PMID: 29734047 DOI: 10.1016/j.ejca.2018.04.004] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2017] [Revised: 12/07/2017] [Accepted: 04/05/2018] [Indexed: 12/31/2022]
Abstract
BACKGROUND In recurrent or metastatic (R/M) skin squamous cell cancer (sSCC) not amenable to radiotherapy (RT) or surgery, chemotherapy (CT) has a palliative intent and limited clinical responses. The role of oral pan-HER inhibitor dacomitinib in this setting was investigated within a clinical trial. METHODS Patients with diagnosis of R/M sSCC were treated. Dacomitinib was started at a dose of 30 mg daily (QD) for 15 d, followed by 45 mg QD. Primary end-point was response rate (RR). Tumour samples were analysed through next-generation sequencing using a custom panel targeting 36 genes associated with sSCC. RESULTS Forty-two patients (33 men; median age 77 years) were treated. Most (86%) received previous treatments consisting in surgery (86%), RT (50%) and CT (14%). RR was 28% (2% complete response; 26% partial response), disease control rate was 86%. Median progression-free survival and overall survival were 6 and 11 months, respectively. Most patients (93%) experienced at least one adverse event (AE): diarrhoea, skin rash (71% each), fatigue (36%) and mucositis (31%); AEs grade 3-4 occurred in 36% of pts. In 16% of cases, treatment was discontinued because of drug-related toxicity. TP53, NOTCH1/2, KMT2C/D, FAT1 and HER4 were the most frequently mutated genes. BRAF, NRAS and HRAS mutations were more frequent in non-responders, and KMT2C and CASP8 mutations were restricted to this subgroup. CONCLUSIONS In sSCC, dacomitinib showed activity similar to what was observed with anti-epidermal growth factor receptor agents, and durable clinical benefit was observed. Safety profile was comparable to previous experiences in other cancers. Molecular pt selection could improve therapeutic ratio.
Collapse
Affiliation(s)
- S Cavalieri
- Fondazione IRCCS Istituto Nazionale Dei Tumori, Medical Oncology/Head and Neck Unit, Milan, Italy
| | - F Perrone
- Fondazione IRCCS Istituto Nazionale Dei Tumori, Department of Pathology, Unit of Experimental Molecular Pathology, Milan, Italy
| | - R Miceli
- Fondazione IRCCS Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trial Organization, Milan, Italy
| | - P A Ascierto
- Istituto Nazionale Tumori Fondazione "G. Pascale", Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Naples, Italy
| | - L D Locati
- Fondazione IRCCS Istituto Nazionale Dei Tumori, Medical Oncology/Head and Neck Unit, Milan, Italy
| | - C Bergamini
- Fondazione IRCCS Istituto Nazionale Dei Tumori, Medical Oncology/Head and Neck Unit, Milan, Italy
| | - R Granata
- Fondazione IRCCS Istituto Nazionale Dei Tumori, Medical Oncology/Head and Neck Unit, Milan, Italy
| | - S Alfieri
- Fondazione IRCCS Istituto Nazionale Dei Tumori, Medical Oncology/Head and Neck Unit, Milan, Italy
| | - C Resteghini
- Fondazione IRCCS Istituto Nazionale Dei Tumori, Medical Oncology/Head and Neck Unit, Milan, Italy
| | - D Galbiati
- Fondazione IRCCS Istituto Nazionale Dei Tumori, Medical Oncology/Head and Neck Unit, Milan, Italy
| | - A Busico
- Fondazione IRCCS Istituto Nazionale Dei Tumori, Department of Pathology, Unit of Experimental Molecular Pathology, Milan, Italy
| | - N Paielli
- Fondazione IRCCS Istituto Nazionale Dei Tumori, Department of Pathology, Unit of Experimental Molecular Pathology, Milan, Italy
| | - R Patuzzo
- Fondazione IRCCS Istituto Nazionale Dei Tumori, Melanoma and Sarcoma Surgery Unit, Milan, Italy
| | - A Maurichi
- Fondazione IRCCS Istituto Nazionale Dei Tumori, Melanoma and Sarcoma Surgery Unit, Milan, Italy
| | - G Gallino
- Fondazione IRCCS Istituto Nazionale Dei Tumori, Melanoma and Sarcoma Surgery Unit, Milan, Italy
| | - R Ruggeri
- Fondazione IRCCS Istituto Nazionale Dei Tumori, Melanoma and Sarcoma Surgery Unit, Milan, Italy
| | - L Mariani
- Fondazione IRCCS Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trial Organization, Milan, Italy
| | - M Palla
- Istituto Nazionale Tumori Fondazione "G. Pascale", Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Naples, Italy
| | - L Licitra
- Fondazione IRCCS Istituto Nazionale Dei Tumori, Medical Oncology/Head and Neck Unit, Milan, Italy; Università Degli Studi di Milano, Medical Oncology Department, Milan, Italy
| | - P Bossi
- Fondazione IRCCS Istituto Nazionale Dei Tumori, Medical Oncology/Head and Neck Unit, Milan, Italy.
| |
Collapse
|
26
|
Galli G, Cavalieri S, Di Guardo L, Cimminiello C, Corti F, Nichetti F, Garcia M, Tana S, Fallai C, de Braud F, Platania M, Del Vecchio M. Combination of brain radiotherapy (RT) and immunotherapy (IT) in a single Institution cohort of patients (pts) with metastatic melanoma (MM). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx711.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Alfieri S, Bossi P, Galbiati D, Giannoccaro M, Pilotti S, Perrone F, Paielli N, Tonella L, Bergamini C, Granata R, Resteghini C, Cavalieri S, Iacovelli N, Orlandi E, Locati L, Licitra L, Canevari S, De Cecco L. Gene-expression profiles of primary and metastatic lesions in head and neck squamous cell carcinoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx430.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Galli G, Cavalieri S, Di Guardo L, Cimminiello C, Corti F, Nichetti F, Garcia M, Tana S, Fallai C, de Braud F, Platania M, Del Vecchio M. Brain radiotherapy (RT) and immunotherapy (IT) for metastatic melanoma (MM): a retrospective single institution experience. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx428.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
29
|
Bossi P, Cavalieri S, Perrone F, Miceli R, Ascierto P, Locati L, Bergamini C, Granata R, Alfieri S, Resteghini C, Galbiati D, Busico A, Paielli N, Patuzzo R, Maurichi A, Gallino G, Ruggeri R, Mariani L, Palla M, Licitra L. A phase II trial of dacomitinib in locally advanced unresectable or metastatic skin squamous cell carcinoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
30
|
Cavalieri S, Granata R, Locati L, Bergamini C, Alfieri S, Resteghini C, Galbiati D, Orlandi E, Iacovelli N, Calareso G, Guzzo M, Quattrone P, Licitra L, Bossi P. A single institution twenty-year experience of recurrent or metastatic epithelial non glandular sinonasal cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx430.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Mariani G, Galli G, Cavalieri S, Valagussa P, Bianchi G, Capri G, Cresta S, Ferrari L, Damian S, Duca M, de Braud F, Moliterni A. Long term results of ASTER study, a single Institution phase II trial of sequential chemotherapy (CT) for operable breast cancer (BC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.033] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
32
|
Granata R, Orlandi E, Infante G, Iacovelli N, Miceli R, Cavallo A, Alfieri S, Bergamini C, Resteghini C, Galbiati D, Cavalieri S, Locati L, Tana S, Naimo S, Fallai C, Licitra L, Bossi P. Subsite-dependent prognostic impact of age in patients with nasopharyngeal and oropharyngeal cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx430.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
33
|
Cavalieri S, Granata R, Locati L, Bergamini C, Alfieri S, Resteghini C, Galbiati D, Orlandi E, Iacovelli N, Calareso G, Guzzo M, Quattrone P, Licitra L, Bossi P. Sinonasal non-glandular cancers relapsing after multimodal treatments. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx374.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Roli L, Santi D, Belli S, Tagliavini S, Cavalieri S, De Santis MC, Baraldi E, Fanelli F, Mezzullo M, Granata AR, Pagotto U, Pasquali R, Rochira V, Carani C, Simoni M, Trenti T. The steroid response to human chorionic gonadotropin (hCG) stimulation in men with Klinefelter syndrome does not change using immunoassay or mass spectrometry. J Endocrinol Invest 2017; 40:841-850. [PMID: 28326509 DOI: 10.1007/s40618-017-0653-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/20/2017] [Accepted: 03/06/2017] [Indexed: 02/07/2023]
Abstract
PURPOSE Liquid-chromatography tandem mass-spectrometry (LC-MS/MS) was developed in parallel to Immunoassays (IAs) and today is proposed as the "gold standard" for steroid assays. Leydig cells of men with Klinefelter syndrome (KS) are able to respond to human chorionic gonadotropin (hCG) stimulation, even if testosterone (T) production was impaired. The aim was to evaluate how results obtained by IAs and LC-MS/MS can differently impact on the outcome of a clinical research on gonadal steroidogenesis after hCG stimulation. METHODS A longitudinal, prospective, case-control clinical trial. (clinicaltrial.gov NCT02788136) was carried out, enrolling KS men and healthy age-matched controls, stimulated by hCG administration. Serum steroids were evaluated at baseline and for 5 days after intramuscular injection of 5000 IU hCG using both IAs and LC-MS/MS. RESULTS 13 KS patients (36 ± 9 years) not receiving T replacement therapy and 14 controls (32 ± 8 years) were enrolled. T, progesterone, cortisol, 17-hydroxy-progesterone (17OHP) and androstenedione, were significantly higher using IAs than LC-MS/MS. IAs and LC-MS/MS showed direct correlation for all five steroids, although the constant overestimation detected by IAs. Either methodology found the same 17OHP and T increasing profile after hCG stimulation, with equal areas under the curves (AUCs). CONCLUSIONS Although a linearity between IA and LC-MS/MS is demonstrated, LC-MS/MS is more sensitive and accurate, whereas IA shows a constant overestimation of sex steroid levels. This result suggests the need of reference intervals built on the specific assay. This fundamental difference between these two methodologies opens a deep reconsideration of what is needed to improve the accuracy of steroid hormone assays.
Collapse
Affiliation(s)
- L Roli
- Department of Laboratory Medicine and Pathology Anatomy, Azienda USL of Modena, Modena, Italy
| | - D Santi
- Unit of Endocrinology, NOCSAE, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Via Giardini 1355, 41126, Modena, Italy.
- Department of Medicine, Endocrinology, Metabolism and Geriatrics, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy.
| | - S Belli
- Unit of Endocrinology, NOCSAE, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Via Giardini 1355, 41126, Modena, Italy
| | - S Tagliavini
- Department of Laboratory Medicine and Pathology Anatomy, Azienda USL of Modena, Modena, Italy
| | - S Cavalieri
- Laboratory of Clinical and Endocrinological Analysis, Arcispedale S. Maria Nuova, Reggio Emilia, Italy
| | - M C De Santis
- Department of Laboratory Medicine and Pathology Anatomy, Azienda USL of Modena, Modena, Italy
| | - E Baraldi
- Department of Laboratory Medicine and Pathology Anatomy, Azienda USL of Modena, Modena, Italy
| | - F Fanelli
- Endocrinology Unit and Centre for Applied Biomedical Research, Department of Medical and Surgical Sciences, Alma Mater University of Bologna, S. Orsola-Malpighi Hospital, 40138, Bologna, Italy
| | - M Mezzullo
- Endocrinology Unit and Centre for Applied Biomedical Research, Department of Medical and Surgical Sciences, Alma Mater University of Bologna, S. Orsola-Malpighi Hospital, 40138, Bologna, Italy
| | - A R Granata
- Department of Medicine, Endocrinology, Metabolism and Geriatrics, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy
| | - U Pagotto
- Endocrinology Unit and Centre for Applied Biomedical Research, Department of Medical and Surgical Sciences, Alma Mater University of Bologna, S. Orsola-Malpighi Hospital, 40138, Bologna, Italy
| | - R Pasquali
- Endocrinology Unit and Centre for Applied Biomedical Research, Department of Medical and Surgical Sciences, Alma Mater University of Bologna, S. Orsola-Malpighi Hospital, 40138, Bologna, Italy
| | - V Rochira
- Unit of Endocrinology, NOCSAE, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Via Giardini 1355, 41126, Modena, Italy
- Department of Medicine, Endocrinology, Metabolism and Geriatrics, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy
| | - C Carani
- Unit of Endocrinology, NOCSAE, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Via Giardini 1355, 41126, Modena, Italy
| | - M Simoni
- Unit of Endocrinology, NOCSAE, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Via Giardini 1355, 41126, Modena, Italy
- Department of Medicine, Endocrinology, Metabolism and Geriatrics, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy
- Center for Genomic Research, University of Modena and Reggio Emilia, Modena, Italy
| | - T Trenti
- Department of Laboratory Medicine and Pathology Anatomy, Azienda USL of Modena, Modena, Italy
| |
Collapse
|
35
|
Di Gregorio E, Riberi E, Belligni EF, Biamino E, Spielmann M, Ala U, Calcia A, Bagnasco I, Carli D, Gai G, Giordano M, Guala A, Keller R, Mandrile G, Arduino C, Maffè A, Naretto VG, Sirchia F, Sorasio L, Ungari S, Zonta A, Zacchetti G, Talarico F, Pappi P, Cavalieri S, Giorgio E, Mancini C, Ferrero M, Brussino A, Savin E, Gandione M, Pelle A, Giachino DF, De Marchi M, Restagno G, Provero P, Cirillo Silengo M, Grosso E, Buxbaum JD, Pasini B, De Rubeis S, Brusco A, Ferrero GB. Copy number variants analysis in a cohort of isolated and syndromic developmental delay/intellectual disability reveals novel genomic disorders, position effects and candidate disease genes. Clin Genet 2017; 92:415-422. [PMID: 28295210 DOI: 10.1111/cge.13009] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2017] [Revised: 02/28/2017] [Accepted: 03/02/2017] [Indexed: 12/14/2022]
Abstract
BACKGROUND Array-comparative genomic hybridization (array-CGH) is a widely used technique to detect copy number variants (CNVs) associated with developmental delay/intellectual disability (DD/ID). AIMS Identification of genomic disorders in DD/ID. MATERIALS AND METHODS We performed a comprehensive array-CGH investigation of 1,015 consecutive cases with DD/ID and combined literature mining, genetic evidence, evolutionary constraint scores, and functional information in order to assess the pathogenicity of the CNVs. RESULTS We identified non-benign CNVs in 29% of patients. Amongst the pathogenic variants (11%), detected with a yield consistent with the literature, we found rare genomic disorders and CNVs spanning known disease genes. We further identified and discussed 51 cases with likely pathogenic CNVs spanning novel candidate genes, including genes encoding synaptic components and/or proteins involved in corticogenesis. Additionally, we identified two deletions spanning potential Topological Associated Domain (TAD) boundaries probably affecting the regulatory landscape. DISCUSSION AND CONCLUSION We show how phenotypic and genetic analyses of array-CGH data allow unraveling complex cases, identifying rare disease genes, and revealing unexpected position effects.
Collapse
Affiliation(s)
- E Di Gregorio
- University of Torino, Department of Medical Sciences, Turin, Italy.,Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - E Riberi
- Department of Public Health and Pediatrics, University of Torino, Turin, Italy
| | - E F Belligni
- Department of Public Health and Pediatrics, University of Torino, Turin, Italy
| | - E Biamino
- Department of Public Health and Pediatrics, University of Torino, Turin, Italy
| | - M Spielmann
- Research Group Mundlos, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - U Ala
- Computational Biology Unit, Molecular Biotechnology Center (MBC), Turin, Italy.,Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy
| | - A Calcia
- University of Torino, Department of Medical Sciences, Turin, Italy
| | - I Bagnasco
- Neuropsichiatria Infantile, Martini Hospital, ASL TO1, Turin, Italy
| | - D Carli
- University of Torino, Department of Medical Sciences, Turin, Italy
| | - G Gai
- Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - M Giordano
- Department of Health Sciences, Laboratory of Genetics, University of Eastern Piedmont and Interdisciplinary Research Center of Autoimmune Diseases, Novara, Italy
| | - A Guala
- SOC Pediatria, Castelli Hospital, Verbania, Italy
| | - R Keller
- Mental Health Department, ASL TO2, Adult Autism Center, Turin, Italy
| | - G Mandrile
- Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy.,Medical Genetics, San Luigi Gonzaga University Hospital, Orbassano (TO), Italy
| | - C Arduino
- Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - A Maffè
- Molecular Biology and Genetics Unit, Santa Croce e Carle Hospital, Cuneo, Italy
| | - V G Naretto
- Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - F Sirchia
- Molecular Biology and Genetics Unit, Santa Croce e Carle Hospital, Cuneo, Italy
| | - L Sorasio
- Pediatrics, Santa Croce e Carle Hospital, Cuneo, Italy
| | - S Ungari
- Molecular Biology and Genetics Unit, Santa Croce e Carle Hospital, Cuneo, Italy
| | - A Zonta
- Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - G Zacchetti
- Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy.,Department of Health Sciences, Laboratory of Genetics, University of Eastern Piedmont and Interdisciplinary Research Center of Autoimmune Diseases, Novara, Italy
| | - F Talarico
- Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - P Pappi
- Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - S Cavalieri
- University of Torino, Department of Medical Sciences, Turin, Italy
| | - E Giorgio
- University of Torino, Department of Medical Sciences, Turin, Italy
| | - C Mancini
- University of Torino, Department of Medical Sciences, Turin, Italy
| | - M Ferrero
- University of Torino, Department of Medical Sciences, Turin, Italy
| | - A Brussino
- University of Torino, Department of Medical Sciences, Turin, Italy
| | - E Savin
- Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - M Gandione
- Department of Neuropsychiatry, University of Torino, Turin, Italy
| | - A Pelle
- Medical Genetics, San Luigi Gonzaga University Hospital, Orbassano (TO), Italy.,Department of Clinical and Biological Sciences, University of Torino, Turin, Italy
| | - D F Giachino
- Medical Genetics, San Luigi Gonzaga University Hospital, Orbassano (TO), Italy.,Department of Clinical and Biological Sciences, University of Torino, Turin, Italy
| | - M De Marchi
- Medical Genetics, San Luigi Gonzaga University Hospital, Orbassano (TO), Italy.,Department of Clinical and Biological Sciences, University of Torino, Turin, Italy
| | - G Restagno
- Laboratory of Molecular Genetics, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - P Provero
- Computational Biology Unit, Molecular Biotechnology Center (MBC), Turin, Italy.,Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy
| | - M Cirillo Silengo
- Department of Public Health and Pediatrics, University of Torino, Turin, Italy
| | - E Grosso
- Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - J D Buxbaum
- Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York.,Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.,Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - B Pasini
- Molecular Biology and Genetics Unit, Santa Croce e Carle Hospital, Cuneo, Italy
| | - S De Rubeis
- Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York
| | - A Brusco
- University of Torino, Department of Medical Sciences, Turin, Italy.,Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - G B Ferrero
- Department of Public Health and Pediatrics, University of Torino, Turin, Italy
| |
Collapse
|
36
|
Resteghini C, Cavalieri S, Galbiati D, Granata R, Alfieri S, Bergamini C, Bossi P, Licitra L, Locati LD. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients. Best Pract Res Clin Endocrinol Metab 2017; 31:349-361. [PMID: 28911730 DOI: 10.1016/j.beem.2017.04.012] [Citation(s) in RCA: 51] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Four tyrosine kinase inhibitors (TKIs) have been recently licensed in thyroid cancer (TC), sorafenib and lenvatinib for differentiated TC, vandetanib and cabozantinib for medullary TC. Others TKIs such as axitinib, pazopanib, sunitinib, have been tested within phase II trials. The toxicity burden associated to TKIs is not negligible. Drug reductions and interruptions are common, definitive drug withdrawals have also been reported as well as toxic deaths in more rare cases. In this context, the prevention of toxicities is mandatory to allow patients to stay on treatment as long as possible without dose and schedule modifications. Both physicians and patients should be educated to recognize drug-related toxicities in order to manage them in an early phase. Tools (e.g. toxicities summary booklet) for physicians and patients could be considered to improve the knowledge on side effects management. Guidelines, whenever available, should be followed.
Collapse
Affiliation(s)
- C Resteghini
- Head & Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - S Cavalieri
- Head & Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - D Galbiati
- Head & Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - R Granata
- Head & Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - S Alfieri
- Head & Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - C Bergamini
- Head & Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - P Bossi
- Head & Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - L Licitra
- Head & Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; University of Milan, Milan, Italy
| | - L D Locati
- Head & Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
| |
Collapse
|
37
|
Corsi C, Liontos I, Bellini M, Cavalieri S, Cancio Pastor P, Siciliani de Cumis M, Eramo R. Ultimate Limit in the Spectral Resolution of Extreme Ultraviolet Frequency Combs. Phys Rev Lett 2017; 118:143201. [PMID: 28430481 DOI: 10.1103/physrevlett.118.143201] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/26/2016] [Indexed: 06/07/2023]
Abstract
We present the results of direct interferometric measurements on the pulse-to-pulse phase jitter of a metrological, fiber-based, infrared (IR) frequency comb. We show that the short-time evolution of such phase fluctuations, which cannot be actively controlled by any feedback system, imposes a stringent limit on the tooth linewidth of extreme ultraviolet (XUV) combs produced by high-order harmonic conversion, thus explaining the difference of 9 orders of magnitude between the coherence times of state-of-the-art IR and XUV frequency combs.
Collapse
Affiliation(s)
- C Corsi
- European Laboratory for Non-Linear Spectroscopy (LENS), Via N. Carrara 1, I-50019 Sesto Fiorentino, Firenze, Italy
| | - I Liontos
- European Laboratory for Non-Linear Spectroscopy (LENS), Via N. Carrara 1, I-50019 Sesto Fiorentino, Firenze, Italy
| | - M Bellini
- European Laboratory for Non-Linear Spectroscopy (LENS), Via N. Carrara 1, I-50019 Sesto Fiorentino, Firenze, Italy
- Dipartimento di Fisica e Astronomia, Università di Firenze, Via G. Sansone 1, I-50019 Sesto Fiorentino, Firenze, Italy
- Istituto Nazionale di Ottica (INO-CNR), Largo E. Fermi 6, I-50125 Firenze, Italy
| | - S Cavalieri
- European Laboratory for Non-Linear Spectroscopy (LENS), Via N. Carrara 1, I-50019 Sesto Fiorentino, Firenze, Italy
- Dipartimento di Fisica e Astronomia, Università di Firenze, Via G. Sansone 1, I-50019 Sesto Fiorentino, Firenze, Italy
| | - P Cancio Pastor
- European Laboratory for Non-Linear Spectroscopy (LENS), Via N. Carrara 1, I-50019 Sesto Fiorentino, Firenze, Italy
- Dipartimento di Fisica e Astronomia, Università di Firenze, Via G. Sansone 1, I-50019 Sesto Fiorentino, Firenze, Italy
- Istituto Nazionale di Ottica (INO-CNR), Largo E. Fermi 6, I-50125 Firenze, Italy
| | - M Siciliani de Cumis
- European Laboratory for Non-Linear Spectroscopy (LENS), Via N. Carrara 1, I-50019 Sesto Fiorentino, Firenze, Italy
- Istituto Nazionale di Ottica (INO-CNR), Largo E. Fermi 6, I-50125 Firenze, Italy
- Agenzia Spaziale Italiana (ASI), Contrada Terlecchia, I-75100 Matera, Italia
| | - R Eramo
- European Laboratory for Non-Linear Spectroscopy (LENS), Via N. Carrara 1, I-50019 Sesto Fiorentino, Firenze, Italy
- Dipartimento di Fisica e Astronomia, Università di Firenze, Via G. Sansone 1, I-50019 Sesto Fiorentino, Firenze, Italy
- Istituto Nazionale di Ottica (INO-CNR), Largo E. Fermi 6, I-50125 Firenze, Italy
| |
Collapse
|
38
|
Cavalieri S, Nichetti F, Morelli D, de Braud F, Martinetti A, Sottotetti E, Dotti K, Prisciandaro M, Corti F, Platania M. Pro-GRP in small cell lung cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx088.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
39
|
Abstract
BACKGROUND Mathematical and computational models showed to be a very important support tool for the comprehension of the immune system response against pathogens. Models and simulations allowed to study the immune system behavior, to test biological hypotheses about diseases and infection dynamics, and to improve and optimize novel and existing drugs and vaccines. Continuous models, mainly based on differential equations, usually allow to qualitatively study the system but lack in description; conversely discrete models, such as agent based models and cellular automata, permit to describe in detail entities properties at the cost of losing most qualitative analyses. Petri Nets (PN) are a graphical modeling tool developed to model concurrency and synchronization in distributed systems. Their use has become increasingly marked also thanks to the introduction in the years of many features and extensions which lead to the born of "high level" PN. RESULTS We propose a novel methodological approach that is based on high level PN, and in particular on Colored Petri Nets (CPN), that can be used to model the immune system response at the cellular scale. To demonstrate the potentiality of the approach we provide a simple model of the humoral immune system response that is able of reproducing some of the most complex well-known features of the adaptive response like memory and specificity features. CONCLUSIONS The methodology we present has advantages of both the two classical approaches based on continuous and discrete models, since it allows to gain good level of granularity in the description of cells behavior without losing the possibility of having a qualitative analysis. Furthermore, the presented methodology based on CPN allows the adoption of the same graphical modeling technique well known to life scientists that use PN for the modeling of signaling pathways. Finally, such an approach may open the floodgates to the realization of multi scale models that integrate both signaling pathways (intra cellular) models and cellular (population) models built upon the same technique and software.
Collapse
Affiliation(s)
- Marzio Pennisi
- Department of Mathematics and Computer Science, University of Catania, Catania, Italy
| | - Salvatore Cavalieri
- Department of Electrical Electronic and Computer Engineering (DIEEI), University of Catania, Catania, Italy
| | - Santo Motta
- Department of Mathematics and Computer Science, University of Catania, Catania, Italy
| | | |
Collapse
|
40
|
Bregni G, Meneghini E, Galli G, Cavalieri S, Di Salvo F, Amash H, Paolini B, De Braud F, De Santis M, Sant M, Di Cosimo S. Breast cancer Ki67, tumor size and axillary nodes relationship: it's complicated. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw364.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Agustoni F, Fucà G, Corrao G, Vernieri C, Cavalieri S, Raimondi A, Peverelli G, Prisciandaro M, Indelicato P, Dotti K, Morano F, Russo G, Signorelli D, Proto C, Vitali M, Imbimbo M, Zilembo N, Garassino M, De Braud F, Platania M. Impact of hyponatremia in a tertiary cancer center: a one-year-survey at National Cancer Institute of Milan. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw390.37] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Di Cosimo S, Dugo M, Appierto V, Cavalieri S, Angeloni V, Galli G, Bregni G, Cappelletti V, Paolini B, Perrone F, Tiberio P, de Braud F. It's not the quality but the quantity: tumor mutation spectrum and response to neoadjuvant therapy in triple negative breast cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw337.36] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
43
|
Cavalieri S, Raimondi A, Morelli D, Martinetti A, de Braud F, Agustoni F, Dotti K, Galli G, Vernieri C, Fucà G, Peverelli G, Prisciandaro M, Nichetti F, Indelicato P, Lo Russo G, Prinzi N, Garassino M, Platania M. Pro-gastrin releasing peptide (pro-GRP) in small cell lung cancer staging. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw332.34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
44
|
Agustoni F, Fucà G, Corrao G, Vernieri C, Cavalieri S, Raimondi A, Peverelli G, Prisciandaro M, Indelicato P, Lo Russo G, Signorelli D, Proto C, Vitali M, Imbimbo M, Zilembo N, Garassino M, Procopio G, de Braud F, Morelli D, Platania M. Impact of Hyponatremia in a Tertiary Cancer Center: a one-year-Survey at National Cancer Institute of Milan. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw345.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
45
|
Galli G, Bregni G, Meneghini E, Cavalieri S, Di Salvo F, Amash H, Paolini B, de Braud F, De Santis M, Sant M, Di Cosimo S. Ki67, tumor stage (TS) and axillary node metastases (ANMs): a complex relationship. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw337.02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Cavalieri S, Rotoli M, Feliciani C, Amerio P. Expression of the High-Affinity Laminin Receptor (67 kDa) in Normal Human Skin and Appendages. Int J Immunopathol Pharmacol 2016; 18:223-31. [PMID: 15888241 DOI: 10.1177/039463200501800205] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
The interaction of cells with extracellular matrix components plays a significant role in the regulation of cell biology. Laminin is a large glycoprotein involved in fundamental interactions between cells and the basement membrane. Several cell surface receptors are responsible for cell-matrix interactions. The 67 kDa high affinity laminin receptor, 67LR, is involved in the adhesion of normal cells to the laminin network and is also associated with the metastatic phenotype of some tumoral cells. We have investigated the expression of laminin and of the 67LR in normal human skin using immunoperoxidase staining. Twenty samples of skin were analyzed. Antibody against laminin reacted in a continuous linear band at the dermal-epidermal junction, as well as basement membranes of hair follicles, sebaceous and eccrine sweat glands, and dermal blood vessels. The epidermis and the follicular epithelium were negative for laminin. The 67LR seemed not to be expressed on the basal surface of basal keratinocytes. The major expression of this receptor may be detected in the upper half of the spinous layer and in the granular layer. The cells of the outer root sheath in hair follicle showed the same immunohistochemical pattern described for epidermis. In sebaceous glands and in eccrine sweat glands the secreting epithelium was positive. Endothelial cells of dermal blood vessels were routinely positive for 67LR. We observed that the expression of the 67LR in normal human skin is mostly located in epidermal areas in which the keratinizing process was particularly advanced.
Collapse
Affiliation(s)
- S Cavalieri
- Department of Dermatology, Catholic University of the Sacred Heart, Rome, Italy
| | | | | | | |
Collapse
|
47
|
Pappalardo F, Russo G, Candido S, Pennisi M, Cavalieri S, Motta S, McCubrey JA, Nicoletti F, Libra M. Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer. PLoS One 2016; 11:e0152104. [PMID: 27015094 PMCID: PMC4807832 DOI: 10.1371/journal.pone.0152104] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2016] [Accepted: 03/08/2016] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Malignant melanoma is an aggressive tumor of the skin and seems to be resistant to current therapeutic approaches. Melanocytic transformation is thought to occur by sequential accumulation of genetic and molecular alterations able to activate the Ras/Raf/MEK/ERK (MAPK) and/or the PI3K/AKT (AKT) signalling pathways. Specifically, mutations of B-RAF activate MAPK pathway resulting in cell cycle progression and apoptosis prevention. According to these findings, MAPK and AKT pathways may represent promising therapeutic targets for an otherwise devastating disease. RESULT Here we show a computational model able to simulate the main biochemical and metabolic interactions in the PI3K/AKT and MAPK pathways potentially involved in melanoma development. Overall, this computational approach may accelerate the drug discovery process and encourages the identification of novel pathway activators with consequent development of novel antioncogenic compounds to overcome tumor cell resistance to conventional therapeutic agents. The source code of the various versions of the model are available as S1 Archive.
Collapse
Affiliation(s)
| | - Giulia Russo
- Department of Drug Sciences, University of Catania, 95125, Catania, Italy
| | - Saverio Candido
- Department of Biomedical and Biotechnological Sciences, University of Catania, 95125, Catania, Italy
| | - Marzio Pennisi
- Department of Mathematics and Computer Science, University of Catania, 95125, Catania, Italy
| | | | - Santo Motta
- Department of Mathematics and Computer Science, University of Catania, 95125, Catania, Italy
| | - James A. McCubrey
- Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, United States of America
| | - Ferdinando Nicoletti
- Department of Biomedical and Biotechnological Sciences, University of Catania, 95125, Catania, Italy
| | - Massimo Libra
- Department of Biomedical and Biotechnological Sciences, University of Catania, 95125, Catania, Italy
| |
Collapse
|
48
|
Corsi C, Liontos I, Cavalieri S, Bellini M, Venturi G, Eramo R. An ultrastable Michelson interferometer for high-resolution spectroscopy in the XUV. Opt Express 2015; 23:4106-4113. [PMID: 25836448 DOI: 10.1364/oe.23.004106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
We developed an ultra-stable and accurately-controllable Michelson interferometer to be used in a deeply unbalanced arm configuration for split-pulse XUV Ramsey-type spectroscopy with high-order laser harmonics. The implemented active and passive stabilization systems allow one to reach instabilities in the nanometer range over meters of relative optical path differences. Producing precisely delayed pairs of pump pulses will generate XUV harmonic pulses that may significantly improve the achievable spectral resolution and the precision of absolute frequency measurements in the XUV.
Collapse
|
49
|
Zaccara E, Maglione W, Onida F, Annaloro C, Saporiti G, Giordano R, Sambataro D, Cavalieri S, Cortelezzi A, Del Papa N. OP0025 Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis is Effective in Inducing Prolonged Remission of Disease Activity: Results from Long-Term Follow-Up. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.4375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
50
|
Rossi E, Regolisti G, Perazzoli F, Negro A, Grasselli C, Santi R, Cavalieri S, Belloni L, Gemelli G, Valle ED, Miotto D. Intraprocedural cortisol measurement increases adrenal vein sampling success rate in primary aldosteronism. Am J Hypertens 2011; 24:1280-5. [PMID: 21850058 DOI: 10.1038/ajh.2011.148] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Adrenal venous sampling (AVS) is the gold standard for the identification of unilateral primary aldosteronism (PA), but is technically difficult. The aim of our study was to assess whether intraprocedural cortisol measurement (IPCM) increases AVS success rate. METHODS Twenty-five consecutive PA patients underwent cosyntropin-stimulated AVS. Cortisol was measured immediately in a first set of samples drawn from adrenal veins and inferior vena cava. The selectivity criterion was an adrenal vein-to-inferior vena cava cortisol ratio ≥5. If bilateral selectivity was not achieved in a first set of samples, a second set was obtained during the same radiological session. PA was judged as unilateral if the gradient of cortisol-corrected aldosterone between dominant and nondominant side was >3.5. Twenty-five consecutive PA patients who had previously been submitted to AVS without IPCM served as historical controls. Lateralizing patients who underwent unilateral adrenalectomy were followed for 2 years after surgery. RESULTS Bilateral selectivity using IPCM was achieved in 19/25 patients in the first set of samples, and in an additional four cases in the second set (92% vs. 76%; P = 0.06). The final rate of bilateral selectivity was higher than that obtained in the historical series (23/25 vs. 16/25, P = 0.04), whereas bilateral selectivity in the first set of samples was not different from that achieved in the historical series. Nineteen lateralizing patients (13 of the present series, six of the historical series) were submitted to adrenalectomy, resulting in reversal of PA. CONCLUSIONS IPCM increases the success rate of AVS.
Collapse
|